The family of G‐protein‐coupled receptors

The family of G‐protein‐coupled receptors can be defined by their similar structural and functional characteristics. Although their primary sequences are quite diverse, these proteins share several common structural features that reflect their common mechanism of action. Mutagenesis and biophysical analysis of several of these receptors indicate that small molecule agonists and antagonists bind to a hydrophobic pocket buried in the transmembrane core of the receptor. In contrast, peptide ligands bind to both the extracellular and transmembrane domains. The mechanisms by which these peptide and small molecule agonists cause receptor activation are being explored by various approaches, but are not yet well defined. A deeper understanding of structural basis for the functional activity of this large family of receptors will have important implications for drug design in a variety of therapeutic areas.—Strader, C. D., Fong, T. M., Graziano, M. P., Tota, M. R. The family of G‐protein‐coupled receptors. FASEB J. 9, 745‐754 (1995)

[1]  Catherine,et al.  dentific ~ tion f Two Serine Residues Involved in Agonist Activation of the & Adrenergic Receptor ” , 2022 .

[2]  J. Novotný,et al.  Mutation of peptide binding site in transmembrane region of a G protein-coupled receptor accounts for endothelin receptor subtype selectivity. , 1994, The Journal of biological chemistry.

[3]  S. Nakanishi.  Molecular diversity of glutamate receptors and implications for brain function. , 1992, Science.

[4]  D Eisenberg,et al.  Hydrophobic organization of membrane proteins. , 1989, Science.

[5]  C. Strader,et al.  Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. , 1988, The Journal of biological chemistry.

[6]  L. Stryer,et al.  Transverse location of the retinal chromophore of rhodopsin in rod outer segment disc membranes. , 1982, Journal of molecular biology.

[7]  A. Egloff,et al.  Replacement of lysine‐181 by aspartic acid in the third transmembrane region of endothelin type B receptor reduces its affinity to endothelin peptides and sarafotoxin 6c without affecting G protein coupling , 1992, Journal of cellular biochemistry.

[8]  C. Strader,et al.  Characterization of a fluorescent substance P analog. , 1994, Biochemistry.

[9]  P. Corvol,et al.  Mutation of Asp74 of the rat angiotensin II receptor confers changes in antagonist affinities and abolishes G-protein coupling. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Uhler,et al.  Molecular cloning of a gene encoding the histamine H2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Nakanishi,et al.  Sequence and expression of a metabotropic glutamate receptor , 1991, Nature.

[12]  F J Grant,et al.  Expression cloning and signaling properties of the rat glucagon receptor. , 1993, Science.

[13]  D. Russo,et al.  An insertion in the human thyrotropin receptor critical for high affinity hormone binding. , 1990, Science.

[14]  B. Thorens.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Lefkowitz,et al.  Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. , 1993, Trends in pharmacological sciences.

[16]  K. Hideg,et al.  Photoactivated conformational changes in rhodopsin: a time-resolved spin label study. , 1993, Science.

[17]  Yue Zhang,et al.  Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan. , 1994, The Journal of biological chemistry.

[18]  C. Esmon,et al.  The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. , 1991, The Journal of biological chemistry.

[19]  R. Neubig,et al.  Resonance energy transfer between guanine nucleotide binding protein subunits and membrane lipids. , 1993, Biochemistry.

[20]  Irving S. Sigal,et al.  Ligand binding to the β-adrenergic receptor involves its rhodopsin-like core , 1987, Nature.

[21]  R. Campbell,et al.  Co-evolution of ligand-receptor pairs , 1994, Nature.

[22]  R. Freidinger.  Cholecystokinin and gastrin antagonists , 1989, Medicinal research reviews.

[23]  R. Osman,et al.  Hydrogen bonding interaction of thyrotropin-releasing hormone (TRH) with transmembrane tyrosine 106 of the TRH receptor. , 1994, The Journal of biological chemistry.

[24]  R. Henderson,et al.  Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. , 1990, Journal of molecular biology.

[25]  C. Strader,et al.  Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. , 1989, The Journal of biological chemistry.

[26]  C. Strader,et al.  Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor. , 1992, The Journal of biological chemistry.

[27]  Y. Kaziro,et al.  Molecular cloning and expression of a cDNA encoding the secretin receptor. , 1991, The EMBO journal.

[28]  Y. Yokota,et al.  Delineation of structural domains involved in the subtype specificity of tachykinin receptors through chimeric formation of substance P/substance K receptors. , 1992, The EMBO journal.

[29]  C. Strader,et al.  Interaction of glutamine 165 in the fourth transmembrane segment of the human neurokinin-1 receptor with quinuclidine antagonists. , 1994, The Journal of biological chemistry.

[30]  Brian K. Kobilka,et al.  Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin , 1986, Nature.

[31]  Yi-Jun Guo,et al.  Molecular basis for the interaction of histamine with the histamine H2 receptor. , 1992, The Journal of biological chemistry.

[32]  J. D. Elliott,et al.  Tyr-129 is important to the peptide ligand affinity and selectivity of human endothelin type A receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K Konvicka,et al.  A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. , 1994, Molecular pharmacology.

[34]  C. Turck,et al.  Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface , 1994, Nature.

[35]  J. Demartino,et al.  The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs. , 1994, The Journal of biological chemistry.

[36]  J. Wess,et al.  Site‐directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. , 1991, The EMBO journal.

[37]  M. Freeman,et al.  A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. , 1991, Science.

[38]  H. Jüppner,et al.  The extracellular amino-terminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH-(1-34). , 1994, Endocrinology.

[39]  C. Tsai-Morris,et al.  Intronic nature of the rat luteinizing hormone receptor gene defines a soluble receptor subspecies with hormone binding activity. , 1990, The Journal of biological chemistry.

[40]  K. Neve,et al.  Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. , 1991, Molecular pharmacology.

[41]  Gebhard F. X. Schertler,et al.  Projection structure of rhodopsin , 1993, Nature.

[42]  S. Sealfon,et al.  Glutamate 301 of the mouse gonadotropin-releasing hormone receptor confers specificity for arginine 8 of mammalian gonadotropin-releasing hormone. , 1994, The Journal of biological chemistry.

[43]  S. Nakanishi,et al.  Role of the large extracellular domain of metabotropic glutamate receptors in agonist selectivity determination. , 1993, The Journal of biological chemistry.

[44]  C. Strader,et al.  Localization of the ligand binding site of the neurokinin-1 receptor: interpretation of chimeric mutations and single-residue substitutions. , 1994, Molecular pharmacology.

[45]  H Weinstein,et al.  Signal transduction by a 5-HT2 receptor: a mechanistic hypothesis from molecular dynamics simulations of the three-dimensional model of the receptor complexed to ligands. , 1993, Journal of medicinal chemistry.

[46]  C. Strader,et al.  Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. , 1994, The Journal of biological chemistry.

[47]  E. Escher,et al.  Substance P--structure-activity studies and the development of antagonists. , 1984, Pharmacology.

[48]  C. Strader,et al.  Functional mapping of the ligand binding sites of G‐Protein coupled receptors , 1994, Medicinal research reviews.

[49]  R. Mark,et al.  Amino terminus of the interleukin-8 receptor is a major determinant of receptor subtype specificity. , 1992, The Journal of biological chemistry.

[50]  J. Lowe,et al.  Specific residues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP 96,345 [corrected]. , 1994, The Journal of biological chemistry.

[51]  T. Schwartz,et al.  Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Drysdale,et al.  Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988. , 1992, Journal of medicinal chemistry.

[53]  C. Strader,et al.  Characterization of the binding domain of the beta-adrenergic receptor with the fluorescent antagonist carazolol. Evidence for a buried ligand binding site. , 1990, The Journal of biological chemistry.

[54]  A. Gilman,et al.  G proteins: transducers of receptor-generated signals. , 1987, Annual review of biochemistry.

[55]  C. Strader,et al.  Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor. , 1994, Biochemistry.

[56]  J. Amin,et al.  GABAA receptor needs two homologous domains of the & beta;-subunit for activation by GABA but not by pentobarbital , 1993, Nature.

[57]  C. Strader,et al.  The role of histidine 265 in antagonist binding to the neurokinin-1 receptor. , 1994, The Journal of biological chemistry.

[58]  Terri L. Gilbert,et al.  Cloning, expression, and gene structure of a G protein-coupled glutamate receptor from rat brain. , 1991, Science.

[59]  C. Strader,et al.  Amino–aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345 , 1993, Nature.

[60]  E C Hulme,et al.  Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors. , 1994, The Journal of biological chemistry.

[61]  Laurent Journot,et al.  Differential signal transduction by five splice variants of the PACAP receptor , 1993, Nature.

[62]  L. Sklar,et al.  Evidence for protonation in the human neutrophil formyl peptide receptor binding pocket. , 1993, Biochemistry.

[63]  T. Branchek,et al.  Expression and pharmacological characterization of a canine 5-hydroxytryptamine1D receptor subtype. , 1991, Molecular pharmacology.